In Vitro Antileishmanial, Trypanocidal, and Mammalian Cell Activities of Diverse N,N'-Dihetaryl Substituted Diamines and Related Compounds

Sandra M. LEAL * 1, Diego F. AMADO 2, Vladimir V. KOUZNETSOV 2, Patricia ESCOBAR 1

1 Centro de Investigación de Enfermedades Tropicales, CINTROP, Departamento de Ciencias Básicas, Escuela de Medicina, Universidad Industrial de Santander, Bucaramanga, Colombia.
2 Laboratorio de Química Orgánica y Biomolecular, Escuela de Química, Universidad Industrial de Santander, Bucaramanga, Colombia.

* Corresponding author. E-mail: sandramilena20@gmail.com (S. M. Leal)

Sci Pharm. 2013; 81: 43–55    doi:10.3797/scipharm.1205-14
Published:  October 14th 2012   Received:  May 31st 2012
Accepted:  October 14th 2012

Abstract

The leishmaniasis and Chagas diseases constitute a serious public health problem worldwide with few and ineffective treatment options. The search for new antiparasitic candidates at the initial steps of drug discovery and development is still necessary. The synthesis of 22 de novo synthetized N,N'-dihetaryl-alkyldiamine derivatives and in vitro antiparasitic activity were evaluated for the first time against intracellular and extracellular forms of Leishmania (Leishmania) infantum, L. (Viannia) panamensis, L. (Leishmania) amazonensis, and Trypanosoma cruzi. Additionally, the toxicity on mammalian cells was determined. Some of these substituted N,N'-diamines (25–35 % of the tested compounds) showed interesting results against free-living forms of parasites with activities at the inhibitory concentration (IC50) level of 1.96 to 28.83 µM for L. (L.) infantum promastigotes and IC50 of 0.02 to 5.31 µM for T. cruzi epimastigotes. No activity at the IC50 level on intracellular amastigotes of T. cruzi was observed. However, N1,N2-dibenzylethane-1,2-diamine 5a revealed an important activity against the intracellular amastigotes of L. infantum (IC50 25.42 µM ±0.33) and L. panamensis (IC50 58.20 µM ±3.23), while their analogue N1,N4-dibenzylbutane-1,4-diamine 5c resulted in activity only against L. panamensis (IC50 11.19 µM ±0.20) without toxicity on Vero and THP-1 mammalian cells. The active compounds against intracellular parasites with low
toxicity in mammalian cells may be considered for future studies in experimental models.

Keywords
Leishmania (Leishmania) infantum • Leishmania (Viannia) panamensis • Trypanosoma cruzi • Mammalian cell toxicity • N,N'-Dihetaryl-alkyldiamine derivatives • Drug discovery

Introduction
The leishmaniasis and Chagas diseases represent a major public health problem in various tropical and sub-tropical regions. They are produced by digenetic protozoa living as extracellular parasites on their respective insect vectors and as intracellular amastigotes inside mammalian host cells. Leishmaniasis is caused by many species of protozoa belonging to the genus Leishmania transmitted by the bite of the phlebotomine sandfly. Leishmaniasis currently threatens 350 million people in 88 countries around the world, where 12 million people are affected and 2 million new cases occur each year [1]. There are no effective vaccines and current chemotherapy is based on the use of pentavalent antimonies followed by amphotericin B (AmB), pentamidine isothionate, paramomycin, and miltefosine. They are still not the ideal antileishmanial drug and problems such as low efficacy, high toxicity, and cost and/or high risk of induced resistance are reported [2].

Chagas disease, also known as American Trypanosomiasis, is one of the most serious protozoan diseases that occurs throughout Latin America. It is produced by Trypanosoma cruzi, a flagellate protozoan which is transmitted to humans and other mammals mostly by hematophagous insects of the Reduviidae family, but also congenitally, orally, or by blood transfusion [3]. There are 90–100 million people at risk, with 16–18 million cases [4]. There are no prophylactic drugs to prevent infection, and current chemotherapy is based on two drugs (nifurtimox and benznidazole), effective only for recent infections and for the short-term chronic phase of the disease. Both drugs have severe side-effects, (allergic dermopathy, anorexia, vomiting, peripheral polyneuropathy, and psychic alterations) requiring long courses of treatment, and exhibit variable efficacy [5]. Gentian violet has been used for the prevention of Chagas disease by blood transfusion and some drugs originally developed to treat fungal infections (itraconazole, ketoconazole, posaconazole, and ravuconazole) were evaluated in clinical trials [5, 6].

Thus, the increasing problems derived from the employment of the currently used drugs in treating the leishmaniasis and Chagas diseases have resulted in an urgent need for novel, non-toxic, selective, and cost-effective new drug candidates in this area. During the last few years, a new incentive to discover antileishmanial and antitripanosomal drugs has arisen. Several aspects such as advances in the knowledge of the biology and genome of parasites, bioinformatics and chemical techniques, networks, partnerships, and consortia have supported the development of new antileishmanial agents. Currently, the development of both synthetic and natural drugs have relevant importance in the search of new therapeutic alternatives [6, 7]. In recent years, traditional medicine has great importance in the field of chemotherapy against tropical diseases as an alternative to treatment. Essential oils, plant extracts, oils components, among others with antiparasitic
activity, have been tested against trypanosomatid, however, few natural compounds continue to be tested in in vivo studies [8, 9].

The synthesis of a wide number of polyamine analogs has been prompted and some promising compounds with trypanocidal properties have been obtained. Polyamines are a group of organic cationic molecules practically present in all living organisms. They play vital roles in cell proliferation and differentiation and macromolecular biosynthesis [10]. In trypanosomatids, the mechanism of polyamine transport and synthesis has been studied and important differences between mammalian and parasitic polyamine metabolism have been established, supporting the use of polyamine biosynthesis inhibitors or polyamine derivatives as a promising strategy in the search for antiparasitic drugs [10–13]. A series of N,N'-bis(benzyl) substituted polyamine analogs were found to inhibit L. donovani, T. cruzi, and Plasmodium falciparum parasites in in vitro and animal experimental models [14–16]. Recently, a series of novel diamine derivatives have demonstrated activities against both L. donovani promastigotes and P. falciparum [17], while diverse diamines containing a fatty chain attached to the ethylenediamine fragments or 1,2-cyclohexanediame derivatives were active on L. amazonensis, L. braziliensis, and L. chagasi promastigotes [18, 19]. In addition, N-alkyl lipophilic diamines were highly active against L. amazonensis and L. chagasi promastigotes, where the ethylenediamine derivative contains a 12-carbon alkyl chain substitute [20]. Polyamine derivatives such as bis-naphthalimidopropyl putrescine, spermidine, and spermine were active on L. infantum promastigotes [21].

With these precedents in mind and as a part of a screening program for new molecules with antiparasitic activities [22, 23], the aim of this project was to evaluate the in vitro biological activity against parasites and mammalian cells of several N,N'-dihetaryl substituted diamines and related compounds derived from ethylenediamine, 1,3-propandiamine and putrescine.

Results and Discussion

In an attempt to find different small heterocyclic molecules active against protozoan parasites, we decided to prepare some N,N'-dihetaryl substituted diamines de novo whose antiparasitic properties are unknown at the moment. Thus, using a common synthetic method that includes the formation of the N,N'-dihetarylidenalkane-diamines 4a–k from the primary diamines (ethylenediamine 1, 1,3-propanediamine 2, putrescine 3) and benzaldehydes (pyridincarboxyaldehydes) as precursors, and the imine’s reduction by treatment with excess NaBH₄ in methanol, the desired N,N'-alkane-diamines with aryl (comp. 5a–e) or pyridinyl (comp. 5h–j) moities were easily synthetized [24–27]. The bis-thiazolidinones 6a,c and 6f–k, joined through ethylene spacers, were obtained via the condensation of α-mercaptoacetic acid and diamiines 4 following our previously reported protocol [28]. The simple diamine precursors 1–3 and the N¹,N⁴-dibenzylbutane-1,4-diamine 5c were chloroacetylated with chloroacetyl chloride at −40 °C to achieve the respective chloroacetyl amides 7a–c and 8 (Sch. 1).

Having these diamine molecules on our hands, we proceeded to perform biological assays. First, in vitro activity on L. (L.) infantum promastigotes and T. cruzi epimastigotes of the selected molecules 5–8 was studied. Analyzing the obtained results (Tab. 1), we found that four compounds, 5a–c and 8, were active on promastigotes of L. chagasi with activities ranging from IC₅₀ 1.96 ± 0.07 to 12.19 ± 2.45 µM (p<0.05). Four compounds,
5a,d,e and 8, exhibited potent activity (from IC$_{50}$ 0.02 ± 0.004 to 2.54 ± 0.08 µM) against T. cruzi epimastigotes, being more active than the reference drug (nifurtimox, p<0.05). Moreover, their selective index (SI) was higher than 6.4 indicating parasite-selective activity. The benzyl disubstituted diamine 5a, having two carbons as a spacer, and the dichloroacetamide dibenzyl substituted diamine 8, with four carbons as a spacer, were active against both parasitic free-living forms. In contrast, dibenzyl diamine analogues 5b,d were more selective towards the epimastigotes of T. cruzi. Surprisingly, a series of new bis-thiazolidinones joined through a methylenic spacer (comp. 6a,c and 6f–k) appeared to be inactive. Other authors have reported similar results in terms of the antiparasitic activity of N, N-substituted diamines. Caminos et al, [29] reported an IC$_{50}$ of less than 10 µM for these compounds against free-living forms of L. donovani and T. cruzi and the bloodstream form of T. brucei with low toxicity on Vero cells. The activities against intracellular parasites were not evaluated in this study. Diverse diamines have been actives also on L. amazonensis, L. braziliensis, and L. chagasi promastigotes with IC$_{50}$ values <10 µg/mL [18, 19].

Sch. 1. Synthesis of functionalized diamines. Reagents and conditions: (a) ArCHO, EtOH, rt, 1 h, 61–100%; (b) ArCHO, EtOH, reflux, 7 h, 64–100%; (c) NaBH$_4$, MeOH, rt, 3-5 h, 53–93%; (d) HSCH$_2$COOH, MeCN, 5 ºC, 1 h, 33–68%; (e) ClCH$_2$COCl, CH$_2$Cl$_2$, Et$_3$N, −40 ºC, 2 h, 61–86%

Following the results from the mammalian cell toxicity tests on Vero and THP-1 cells, we could note that compound 8 was partially toxic to THP-1 cells (CC$_{50}$ 25.05 ± 0.35 and CC$_{90}$ > 207.60), and dichloroacetamides 7a,c were toxic on Vero cells (CC$_{50}$ 25.69 ± 1.22 and 37.11 ± 0.45 µM and CC$_{90}$ 49.50 ± 1.87 and 77.57 ± 3.15 µM, respectively) as shown in
Table 1. In general, all compounds tested showed low toxicity, however, other studies of toxicity such as genotoxicity, teratogenicity, mutagenicity, among others, are necessary to continue with the following experimental phases in vivo. Furthermore, compounds active in both free and intracellular forms showed an IS> 6, indicating that biological activity could be directed primarily against the parasite and not against host cells suggesting the selectivity of the compound.

| Cpd. | Structure/Molecular Formula | Log P | L. (L) infantum promastigotes IC$_{50}$ ± SD$^a$ | T. cruzi epimastigotes IC$_{50}$ ± SD$^b$ | THP-1 Mammalian cells CC$_{50}$ ± SD$^c$ | Vero Mammalian cells CC$_{50}$ ± SD$^c$ |
|------|-----------------------------|-------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| 5a   | ![Structure](image)          | 3.58  | 12.19 ± 2.45                   | 19.58 ± 0.08                   | 29.62 ± 17.93                  | 75.26 ± 2.57                    |
| 5b   | ![Structure](image)          | 3.62  | 1.96 ± 0.07                    | 86.29 ± 5.35                   | 64.2 ± 29.76                   | 343.48 ± 29.37                  |
| 5c   | ![Structure](image)          | 3.92  | 11.23 ± 0.11                   | 12.75 ± 1.66                   | 0.53 ± 13.35                   | 60.37 ± 2.42                    |
| 5d   | ![Structure](image)          | 1.52  | 40.24 ± 5.21                   | >7.48 ± 0.06                   | >300 ± 200                     | >300 ± 200                      |
| 5e   | ![Structure](image)          | 1.96  | >250 ± 0.89                    | 1.22 ± 0.08                    | >200 ± 247.91                  | >250 ± 247.91                   |
| 5h   | ![Structure](image)          | 0.58  | 180.54 ± 1.89                  | >2.28 ± 0.86                   | >0.86 ± 412.67                 | 355.64 ± 37.05                  |
| 5i   | ![Structure](image)          | 0.93  | 28.83 ± 5.14                   | >12.82 ± 3.54                  | >0.35 ± 300                    | 131.52 ± 12.31                  |
| 5j   | ![Structure](image)          | 0.93  | 44.19 ± 10.54                  | >8.36 ± 0.72                   | >1 ± 250                      | >300 ± 250                      |
| 6a   | ![Structure](image)          | 4.46  | 135.8 ± 6.96                   | >1.91 ± 12.14                  | 0.72 ± 250                     | 170.84 ± 3.77                   |
| Cpd. | Structure/Molecular Formula | Log $P$ | $L. (L)$ infantum promastigotes | $T. cruzi$ epimastigotes | Mammalian cells |
|------|-----------------------------|---------|---------------------------------|-------------------------|-----------------|
|      |                             |         | IC$_{50}^a$ ± SD | SI$^b$ | IC$_{50}^a$ ± SD | SI | CC$_{50}^c$ ± SD | CC$_{50}^c$ ± SD |
| 6c   | ![Structure](image1.png)    | 4.57    | >250             | >1.0   | >250             | >1.01 | >250             | >250             |
| 6f   | ![Structure](image2.png)    | 1.48    | 176.42 ± 16.04   | >1.46  | 161.22 ± 5.58   | >1.60 | >250             | >250             |
| 6g   | ![Structure](image3.png)    | 1.48    | >250             | >1.0   | >250             | >1.0  | >250             | >250             |
| 6h   | ![Structure](image4.png)    | 1.47    | >250             | >1.0   | >250             | >1.0  | >250             | >250             |
| 6i   | ![Structure](image5.png)    | 1.59    | >250             | >1.0   | >250             | >1.0  | >250             | >250             |
| 6j   | ![Structure](image6.png)    | 1.59    | >250             | >1.0   | 235.03 ± 3.06   | 0.32  | >250             | 75.36 ± 1.80     |
| 6k   | ![Structure](image7.png)    | 1.58    | >250             | >1.0   | >250             | >1.0  | >250             | >250             |
| 7a   | ![Structure](image8.png)    | −1.04   | 176.02 ± 18.97   | >2.66  | 65.94 ± 5.54    | 0.38  | >300             | 25.69 ± 1.22     |
The second part of our study consisted of bio-screening on in vitro activity on intracellular amastigotes of both *Leishmania* spp and *T. cruzi* parasites. From the overall activity of tested molecules, only *N*,*N'*-hetaryl diamines 5a and 5c were active on the intracellular live forms of *Leishmania* parasites. Any compound was active on the intracellular form of *T. cruzi*. The *N*,*N'*-dibenzylethane-1,2-diamine 5a, having a calculated log $P$ = 3.58, showed the best antiparasitic activity on the intracellular amastigotes of *L. (L.) infantum* infecting THP-1 macrophages (IC$_{50}$ values of 25.42 ± 0.33 μM, SI = 9.39, p<0.05) compared with the other species of *Leishmania*. It was also partially active on *L. panamensis*. Interestingly, its closer pyridinylalkane-diamine analogues (comp. 5h–j) did not possess these properties. In contrast, the dibenzyl diamine derivative 5c (log $P$ = 3.92) with four carbons as a spacer showed activity on the intracellular amastigote of *L. panamensis* (Tab. 2). These active compounds may be assessed in future studies in animal models since polyamine analogs have shown in previous reports to inhibit *L. donovanni* in experimental models [14].
Tab. 2. *In vitro* activity of *N*,*N'*-dihetaryl substituted diamines against intracellular amastigotes of *Leishmania* spp and *Trypanosoma cruzi*.

| Cpd. | L. (L.) *infantum* (48.58%) | L. (V.) *panamensis* (78.3%) |
|------|----------------------------|----------------------------|
|      | µM ± SD<sup>a</sup> | µM ± SD<sup>a</sup> | µM ± SD<sup>a</sup> | µM ± SD<sup>a</sup> | µM ± SD<sup>a</sup> |
|      | IC<sub>50</sub><sup>c</sup> | IC<sub>90</sub> | SI<sup>d</sup> | IC<sub>50</sub> | IC<sub>90</sub> | SI |
| 5a   | 25.42 ± 0.33 | 59.54 ± 2.78 | 9 | 58.20 ± 3.23 | 88.13 ± 1.85 | 5 |
| 5c   | 0.045 ± 0.007 | 0.138 ± 0.023 | 360 | 0.032 ± 0.002 | 0.20 ± 0.002 | 420 |
| AmB  | 11.19 ± 0.20 | 41.68 ± 0.76 | ND | 41.68 ± 0.76 | 106.25 ± 13.07 | 0.82 |

Conclusion

This work described the antiparasitic and cytotoxic evaluation of several lipophilic *N*,*N'*-dihetaryl substituted diamines prepared from simple diamines by the iminonization reaction and reduction reaction. During our biological study, we identified several *N*,*N'*-diamines with excellent *in vitro* results against the *Leishmania* spp and/or *T. cruzi* parasites. The activity data suggest that the methylenic spacer bearing two to four carbons may be effective on antiparasitic diamines while the ethane-1,4-diamine skeleton is disubstituted with dibenzyl (comp. 5a) fragments. Also, the dichloroacetamide dibenzyl substituted with four carbons as a methylenic spacer (comp. 8) did work well with better results than the other diamine derivatives.

Correlation between the calculated log *P* values and antiparasitic activities data showed that log *P* parameters were, in general, similar for active as well as for inactive compounds. However, it could be noted that except the compound 5d, which has a log *P* less than 2 (1.52) and compound 5e with log *P* 1.96, molecules 5a–c and 8 with the highest potencies against *T. cruzi* and/or *L. chagasi* had a partition coefficient between the range of 3.58 and 3.92. From these data, we could deduce that the lipophilicity of the tested disubstituted diamines would not have a direct influence on their antiparasitic activity. These results are important data for the design and synthesis of new related diamine derivatives, which could become leaders in the development of antiparasitic agents.
Experimental

Chemicals

Solvents and common reagents were obtained from Merck and Aldrich and were used without further purification. The reaction progress was monitored using thin layer chromatography on a silufol UV254 TLC aluminum sheet. The chemical purity of obtained compounds 5–8 was confirmed using elemental analyses, performed on a Perkin Elmer 2400 Series II analyzer, that were within ± 0.4 of theoretical values. Their spectral and physical properties were in agreement with those reported in literature [22–26].

Biological reagents

Amphotericin B, phorbol mirystate acetate (PMA), dimethylthiazoldiphenyltetrazolium bromide (MTT), HEPES, adenosine, and hemin were purchased from Sigma-Aldrich, USA. Nifurtimox was donated kindly by Professor Simon Croft at the LSHTM, London, UK. Dimethylsulphoxide (DMSO) was obtained from Carlo Erba (Reagenti Rodano, Italy). Culture medium RPMI 1640, fetal calf serum (FCS), and trypsin-EDTA were obtained from Gibco (Grand Island, NY, USA). Stock solutions of the compound and the reference drugs Amphotericin B and nifurtimox were prepared on DMSO (final concentration 0.1%, v/v). Work solutions were made in culture medium immediately before the assays.

Parasite and mammalian cells

Promastigotes forms of L. chagasi (MHOM/BR/74/PP75) syn, L. (L: infantum), L. panamensis (MHOM/PA/71/LS94), and L. amazonensis (MHOM/BR/73/LV78) parasites were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal cow serum (hiFCS) and 0.5 mg/L hemin at 28 °C. Epimastigotes forms of T. cruzi (320I01 strain, kindly donated by K.P. Luna, CINTROP-UIS) [30] were maintained on Liver Infusion Tryptose (LIT) medium with 10% hiFCS at 28 °C.

Vero cells (CCL-81, ATCC) and THP-1 (TIB-202, ATCC) mammalian cells were cultivated in RPMI 1640 medium supplemented with 10% of hiFCS at 37 °C, 5% CO2-95% air mixture.

Parasites assays

Epimastigotes of T. cruzi and promastigotes forms of L. (L.) infantum (5 x 10^5 parasites/mL) were placed in flat-bottomed 96-well microtiter plates (Becton Dickinson, New Jersey, USA) and treated with a three-fold dilution series of the compound (from 0-350 µM) and reference drugs (1.2–100 µM) for 72 h at 28 °C. The inhibition of parasite growth was microscopically determined by counting viable (live) parasites in a haemocytometer using yellow eosin as vital dye; live parasites (uncolored) and dead (orange) were counted. All of the experiments were performed with parasites in their logarithmic phase of growth [31].

For the amastigotes assays, adherent Vero cells or THP-1 macrophages (after transformation with 10 ng/mL PMA) were infected with tissue-derived trypomastigotes or stationary phase promastigotes, respectively, at a ratio of 10:1 and maintained in a 5% CO2-95% air mixture at 37 °C. After 24 h, infected cultures with >50% of infected cells were incubated with the compounds (from 3–300 µM) in a three-fold dilution series for
72 h. Drug activity was determined from the % of infected cells in treated and untreated cultures in fixed methanol and Giemsa stained preparations. Parasites’ assays were performed twice and each tested concentration was tested in triplicate [31].

Amphotericin B and nifurtimox were used as reference drugs in Leishmania and T. cruzi respectively. Negative controls were used without the drug (culture medium alone) in each experiment.

**Mammalian cell assays**

Vero cells and THP-1 cells transformed into adherent macrophages with PMA in 96 microwell plates where they were treated with compounds (0–350 µM) during 72 h at 37 °C, 5% CO₂-95% air mixture. The viability of the cells was evaluated by using the tetrazolium-dye (MTT) colorimetric method. After incubation of the cells with the MTT (5mg/mL) reagent for 4 hours, DMSO was added. The samples were read using an ELISA plate reader at a wavelength of 580 nm. The amount of color produced is directly proportional to the number of viable cells. The percentage of cytotoxicity was calculated by the equation: cytotoxicity (%) = (OD control group- OD treatment group)/ OD control group x 100 [31].

**Statistical analysis**

The antileishmanial and antitrypanosomal activities were expressed as the concentration able to inhibit parasitic growth by 50% (IC₅₀) and 90% (IC₉₀) after a 3-day incubation period. The cytotoxicity of mammalian cells was expressed as the concentration able to kill cells by 50% (CC₅₀) and 90% (CC₉₀) after a 3-day incubation period. The data were calculated by linear regression using the software (Msxlfit; GO Business Solution, Guildford, UK). The selectivity index (SI) was calculated dividing CC₅₀/IC₅₀. Each experiment was repeated twice and the values represent the results of one representative experiment. Active compounds were considered with IC₅₀ <25µM and IC₉₀ <100 µM, partially active with IC₅₀ >25 µM and IC₉₀ <100 µM, and not active with IC₅₀ >25 µM and IC₉₀ >100 µM according to laboratory criteria. The analysis to determine the statistical differences in biological activity was performed using the analysis of variance (ANOVA) and the Bonferroni post-test. We also performed Student’s t test for comparison between the two variables, using GraphPad Prism software version 5.03. P values <0.05 were considered to be statistically significant.

Theoretical values of the partition coefficient (log P) were calculated in the ACD Log PDB (ACD/Labs 6.00) program. The log P of each compound was calculated in order to correlate the qualitative structure-activity relationships with quantitative parameters. It is known that the log P of a drug or drug-like substance is an indicator of the compound lipophilicity and solubility, and it is a useful parameter in drug discovery and development and is issued to predict the transport properties across cell membranes, to establish quantitative structure-activity relationships, and as an indicator of protein-binding characteristics [24].
Acknowledgement
The authors thank the Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología “Francisco José de Caldas” COLCIENCIAS-CENIVAM (Contract No. RC-245-2011) and the Universidad Industrial de Santander, Bucaramanga, for financial support.

Authors' Statement

Competing Interests
The authors declare no conflicts of interest.

References

[1] Leishmaniasis [internet]. World Health Organization. Available from: http://www.who.int/leishmaniasis/en/

[2] Oliveira LF, Schubach AO, Martins MM, Passos SL, Pliveira RV, Marzochi MC, Andrade CA. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica. 2011; 118: 87–96. http://dx.doi.org/10.1016/j.actatropica.2011.02.007

[3] Pinto JC. Elimination of Chagas disease transmission: perspectives. Mem Inst Oswaldo Cruz. 2009; 104: 41–45. http://dx.doi.org/10.1590/S0074-02762009000900007

[4] Coura JR, Borges-Pereira J. Chagas disease: 100 years after its discovery. A systemic review. Acta Tropica. 2010; 115: 5–13. http://dx.doi.org/10.1016/j.actatropica.2010.03.008

[5] Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Tropica. 2010; 115: 55–68. http://dx.doi.org/10.1016/j.actatropica.2009.10.023

[6] Cerecetto H, González M. Synthetic medicinal chemistry in Chagas’ disease: Compounds at the final stage of “hit-to-lead” phase. Pharmaceuticals. 2010; 3: 810–838. http://dx.doi.org/10.3390/ph3040810

[7] Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiasis and leishmaniasis. Trends Parasitol. 2005; 21: 508–512. http://dx.doi.org/10.1016/j.pt.2005.08.026

[8] Alviano DS, Barreto AL, Dias F, Rodrigues I, Santos MdoS, Alviano CS, Soares RM. Conventional therapy and promising plant-derived compounds against trypanosomatid parasites. Front Microbiol. 2012; 3: 283. http://dx.doi.org/10.3389/fmicb.2012.00283

[9] Mohammadpour G, Marzony ET, Farahmand M. Evaluation of the anti-Leishmania major activity of Satureja bakhtiarica essential oil in vitro. Nat Prod Commun. 2012; 7: 133–136. http://www.ncbi.nlm.nih.gov/pubmed/22428267
[10] Heby O, Persson L, Rentala M.
Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas’ disease, and leishmaniasis.
Amino Acids. 2007; 33: 359–366.
http://dx.doi.org/10.1007/s00726-007-0537-9

[11] Roberts SC, Jiang Y, Gasteier J, Frydman B, Marton LJ, Heby O, Ullman B.
Leishmania donovani polyamine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyamine analogs.
Antimicrob Agents Chemother. 2007; 51: 438–445.
http://dx.doi.org/10.1128/AAC.01193-06

[12] Taylor MC, Kaur H, Blessington B, Kelly JM, Wilkinson SR.
Validation of spermidine synthase as a drug target in African trypanosomes.
Biochem J. 2008; 409: 563–569.
http://dx.doi.org/10.1042/BJ20071185

[13] Heby O, Roberts SC, Ullman B.
Polyamine biosynthetic enzymes as drug targets in parasitic protozoa.
Biochem Soc Trans. 2003; 31: 415–419.
http://www.ncbi.nlm.nih.gov/pubmed/12653650

[14] Baumann RJ, McCann PP, Bitonti AJ.
Suppression of Leishmania donovani by oral administration of a bis(benzyl)polyamine analog.
Antimicrob Agents Chemother. 1991; 35: 1403–1407.
http://www.ncbi.nlm.nih.gov/pubmed/1929300

[15] Bitonti AJ, Dumont JA, Bush TL, Edwards ML, Stermerick DM, McCann PP, Sjoerdsma A.
Bis(benzyl)polyamine analogs inhibit the growth of chloroquine-resistant human malaria parasites (Plasmodium falciparum) in vitro and in combination with alpha-difluoromethylornithine cure murine malaria.
Proc Natl Acad Sci U S A. 1989; 86: 651–655.
http://www.ncbi.nlm.nih.gov/pubmed/2463635

[16] Majumder S, Kierszenbaum F.
Inhibition of host cell invasion and intracellular replication of Trypanosoma cruzi by N,N’-bis(benzyl)-substituted polyamine analogs.
Antimicrob Agents Chrmother. 1993; 37: 2235–2238.
http://www.ncbi.nlm.nih.gov/pubmed/8257150

[17] Labadie GR, Choi SR, Avery MA.
Diamine derivatives with antiparasitic activities.
Bioorg Med Chem Lett. 2004; 14: 615–619.
http://dx.doi.org/10.1016/j.bmcl.2003.11.055

[18] Del Olmo E, Alves M, Lopez JL, Inchaustti A, Yaluff G, De Arias AR, San Feliciano A.
Leishmanicidal activity of some aliphatic diamines and amino-alcohols.
Bioorg Med Chem Lett. 2002; 12: 659–662.
http://dx.doi.org/10.1016/S0960-894X(01)00837-X

[19] Rebollo O, del Olmo E, Ruiz G, López-Pérez JL, Jiménez A, San Feliciano A.
Leishmanicidal and trypanocidal activities of 2-aminocyclohexanol and 1,2-cyclohexanediame derivatives.
Bioorg Med Chem Lett. 2008; 18: 184–187.
http://dx.doi.org/10.1016/j.bmcl.2007.10.102

[20] da Costa CF, Coimbra ES, Braga FG, Dos Reis RC, da Silva AD, de Almeida MV.
Preparation and antileishmanial activity of lipophilic N-alkyl diamines.
Biomed Pharmacother. 2008; 63: 40–42.
http://dx.doi.org/10.1016/j.biopha.2007.12.013
[21] Tavares J, Ouaisi A, Lin PKT, Tomas A, Da Silva AC. Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Int J Parasitol. 2005; 35: 637–646. http://dx.doi.org/10.1016/j.ijpara.2005.01.008

[22] Kouznetsov VV, Rivero Castro J, Ochoa Puentes C, Stashenko EE, René Martínez J, Ochoa C, Pereira DM, Ruiz JJ, Portillo CF, Serrano SM, Barrio AG, Bahsas A, Amaro L. Synthesis and antiparasitic properties of new 4-N-benzylamino-4-heteroarylbut-1-enes. Arch Pharm. 2005; 338: 32–37. http://dx.doi.org/10.1002/ardp.200400909

[23] Kouznetsov VV, Vargas Méndez LY, Leal SM, Mora Cruz U, Coronado CA, Meléndez Gómez CM, Romero AR, Escobar P. Target-Oriented Synthesis of Antiparasitic 2-Hetaryl Substituted Quinolines based on imino Diels-Alder reactions. Lett Drug Des Discov. 2007; 4: 293–296. http://dx.doi.org/10.2174/157018007784620031

[24] Harada K, Patai S. The chemistry of the carbon nitrogen double bond. John Wiley and Sons, Inc.: New York 1970; 276–298.

[25] Layer RW. The chemistry of imines. Chem Rev. 1963; 63: 489–510. http://dx.doi.org/10.1021/cr60225a003

[26] Ruiz-Gómez G, Iglesias MJ, Serrano-Ruiz M, Garcia-Granda S, Francesch A, López-Ortiz F, Cuevas C. Double dearomatization of bis(diphenylphosphinamides) through anionic cyclization. A facile route of accessing multifunctional systems with antitumoral properties. J Org Chem. 2007; 72: 3790–3799. http://dx.doi.org/10.1021/jo070276q

[27] Burns MR, Turner SL, Ziemer J, McVean M, Weeks RS, Carreon J. Induction of apoptosis by aryl-substituted diamines: role of aromatic group substituents and distance between nitrogens. Bioorg Med Chem Lett. 2002; 12: 1263–1267. http://dx.doi.org/10.1016/S0960-894X(02)00156-7

[28] Kouznetsov VV, Amado DF, Bahsas A, Amaro-Luis J. Synthesis and Spectral Data of New 1,2-Bis-(2-hetaryl-4-oxothiazolidin-3-yl)ethanes and 1,4-Bis-(2-hetaryl-4-oxothiazolidin-3-yl)butanes. J Heterocycl Chem. 2006; 43: 447–452. http://dx.doi.org/10.1002/jhet.5570430228

[29] Caminos AP, Panozzo-Zenere EA, Wilkinson SR, Tekwani BL, Labadie GR. Synthesis and antikinetoplastid activity of a series of N,N'-substituted diamines. Bioorg Med Chem Lett. 2012; 22: 1712–1715. http://dx.doi.org/10.1016/j.bmcl.2011.12.101

[30] Luna KP, Jaramillo CL, Hernández G, Gutiérrez R, Vallejo GA, Angulo VM. ITS–RFLP-and RAPD-based genetic variability of Trypanosoma cruzi I, human and vector strains in Santander (Colombia). Parasitol Res. 2009; 105: 519–528. http://dx.doi.org/10.1007/s00436-009-1422-0

[31] Gómez S, Castrillón J, Palma A, Leal SM, Escobar P, Bahsas A. Synthesis, structural elucidation and in vitro antiparasitic activity against Trypanosoma cruzi and Leishmania chagasi parasites of novel tetrahydro-1-benzazepine derivatives. Bioorg Med Chem. 2010; 18: 4721–4739. http://dx.doi.org/10.1016/j.bmc.2010.05.018